by | Mar 7, 2024 | Uncategorized
The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Belantamab mafodotin (Blenrep, GSK) is an antibody-drug...
by | Mar 7, 2024 | Uncategorized
Source: ASCO Daily News Drs. John Sweetenham and Shaji Kumar discuss the emergence of CAR T-cell therapy for multiple myeloma, its benefits and challenges for patients, and its potential role earlier in the treatment of disease. TRANSCRIPT Dr. John Sweetenham: Hello,...
by | Feb 23, 2024 | Uncategorized
The FDA announced its final decision to rescind approval of melphalan flufenamide, citing safety concerns.The agency approved melphalan flufenamide (Pepaxto, Oncopeptides) for use in combination with dexamethasone to treat certain patients with multiple myeloma in...
by | Feb 23, 2024 | Uncategorized
Source: CureToday articles Most patients with relapsed or refractory multiple myeloma responded to treatment with the CAR-T cell therapy, Carvykti, according to a small study. Read More
by | Feb 22, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration is reviewing the novel drug, linvoseltamab, for the treatment of patients with pretreated, relapsed or refractory multiple myeloma. Read More
by | Feb 21, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months. Read...
